Xeloda
In brief
- Xeloda (capecitabine) is a prescription-only oncology medicine and should be obtained from a pharmacy with a valid prescription; although there are reports some suppliers or pharmacies may supply medicines without checking a prescription, Xeloda must only be used under a doctor’s supervision.
- Xeloda is used to treat breast, colorectal and gastric cancers; it is an oral prodrug of 5‑fluorouracil (5‑FU), a pyrimidine antimetabolite that is metabolised preferentially in tumours to inhibit DNA synthesis (thymidylate synthase inhibition).
- The usual dose for adults is commonly 1250 mg/m² taken twice daily for 14 days followed by a 7‑day rest (21‑day cycle); lower doses (for example 1000 mg/m² twice daily) may be used for tolerability or specific regimens—individual dosing must be calculated by an oncologist.
- Administration is oral film‑coated tablets (commonly 150 mg and 500 mg tablets) taken twice daily with water, within 30 minutes after a meal as directed by the prescriber.
- Systemic drug levels rise within 1–2 hours after dosing (biochemical onset), but meaningful anti‑cancer effects generally take weeks of treatment and are assessed over cycles by the treating clinician.
- Capecitabine and its active metabolite 5‑FU have short plasma half‑lives (parent drug ~0.5–1 hour; 5‑FU shorter), but clinical effects persist across the dosing cycle—treatment is given in repeated cycles and duration of benefit varies by indication and response.
- Avoid or minimise alcohol while taking Xeloda; alcohol may worsen nausea, vomiting, diarrhoea or liver effects, and you should discuss alcohol use with your oncologist or pharmacist.
- The most common side effects include hand–foot syndrome (palmar‑plantar erythrodysesthesia), diarrhoea, nausea, fatigue and haematological effects; hand–foot syndrome is particularly characteristic and may require dose adjustment.
- Would you like to try xeloda without a prescription?
Critical Warnings & Restrictions
Basic Xeloda Information
- INN (International Nonproprietary Name): Capecitabine.
- Brand Names Available In Australia: Not specified.
- ATC Code: L01BC06.
- Forms & Dosages: Film-coated tablets; strengths listed in product records are 150 mg and 500 mg.
- Manufacturers In Australia: Not specified.
- Registration Status In Australia: Not specified.
- OTC / Rx Classification: Prescription-only (Rx) according to available product information.
High-Risk Groups
Is this medicine safe for everyone, and who should be watched closely?
Xeloda (capecitabine) is a prescription-only anticancer medicine used for breast, colorectal and gastric cancers.
Serious toxicities can occur with capecitabine and may be life‑threatening.
Key toxicities include myelosuppression, severe diarrhoea, hand–foot syndrome and cardiotoxicity.
People taking capecitabine must be monitored closely by their oncology team.
Pregnant and breastfeeding people must not take capecitabine because of teratogenic risk and risk to the infant.
Elderly patients are at higher risk of toxicity due to commonly reduced renal function and comorbidities.
Moderate to severe renal impairment increases exposure to active metabolites and usually requires dose adjustment or avoidance.
Pre‑existing cardiac disease raises concern because cardiotoxicity has been reported with fluoropyrimidines.
Hepatic impairment and immunosuppression increase risk of adverse events and complicate monitoring.
- Checklist For Baseline Tests: Pregnancy test for people of childbearing potential.
- Checklist For Baseline Tests: Baseline full blood count (CBC).
- Checklist For Baseline Tests: Baseline liver function tests (LFTs).
- Checklist For Baseline Tests: Baseline renal function (creatinine/egfr / creatinine clearance).
- Checklist For Baseline Tests: Cardiology review if there is a cardiac history.
| Contraindication / Condition | Why It Matters | Monitoring Frequency |
|---|---|---|
| Pregnancy / Breastfeeding | Teratogenic risk and harm to infant. | Contraindicated; pregnancy test before start; effective contraception during and after treatment per oncology advice. |
| Moderate–Severe Renal Impairment | Increased systemic exposure and toxicity. | Assess renal function before each cycle; consider dose reduction or avoidance. |
| Pre‑existing Cardiac Disease | Risk of cardiotoxicity such as angina or myocardial ischaemia. | Cardiology review prior to start; monitor for chest pain or arrhythmia during treatment. |
| Severe Hepatic Impairment | Metabolism and safety may be affected. | Baseline LFTs and repeat tests as clinically indicated. |
| Immunosuppressed Patients | Higher risk of infection during myelosuppression. | Frequent CBC monitoring; withhold for febrile neutropenia or severe cytopenias. |
Interaction With Activities
Will Xeloda affect daily activities like driving and work?
Capecitabine can cause fatigue, dizziness and visual disturbance in some people.
These effects may impair driving or operating heavy machinery until the individual knows how the medicine affects them.
Australian road and workplace safety laws require that people do not drive or perform safety‑critical tasks if impaired.
People should inform their treating team and employer about any persistent symptoms that may affect safety at work.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking Xeloda?
A: Not until you know how it affects you.
A: If you experience dizziness, visual changes, extreme fatigue or confusion, do not drive or operate machinery.
A: Document any new or worsening symptoms and inform the treating oncology team and the local pharmacist.
A: Your ability to drive should be reassessed after the first cycle or when side effects stabilise and cleared by the treating clinician.
A: If you are performing safety‑critical work, notify your employer and follow local workplace medical guidance.
A: For urgent questions about side effects that affect driving, contact the oncology nurse or pharmacy immediately.
Usage Basics
INN, Brand Names Available In Australia
What is capecitabine called and which brands exist?
The International Nonproprietary Name (INN) is capecitabine.
The primary branded product name documented internationally is Xeloda.
Local brand availability in Australia is not specified in the available product data.
Xeloda tablets are the established brand in many markets and equivalent capecitabine generics exist in some regions.
Legal Classification
Is capecitabine approved and subsidised here?
Capecitabine is an antineoplastic prescription medicine and is included in international regulatory records.
TGA ARTG specifics and sponsor details should be checked on the Australian Register of Therapeutic Goods for the current entry.
Some capecitabine regimens are subsidised under public schemes in various countries for specific indications, but PBS status and criteria in Australia must be verified on the PBS online schedule for current subsidy and authority details.
ATC code is L01BC06 which places capecitabine among pyrimidine analogue antimetabolites.
You will require a prescription from an oncologist to obtain capecitabine in routine practice.
E‑prescriptions and telehealth consults are commonly accepted by treating clinics and community pharmacies, subject to prescribing rules.
Major community pharmacies dispense under PBS rules when criteria are met, and hospital pharmacies often coordinate oncology supply.
Recommended sources to confirm TGA and PBS status include the TGA ARTG entry, PBS online and the product monograph.
Dosing Guide
Standard Regimens
How is capecitabine usually taken?
Xeloda is supplied as film-coated tablets in 150 mg and 500 mg strengths.
Common regimens include twice-daily dosing for 14 days followed by a 7‑day rest in many schedules, but exact dosing depends on the indication and oncology prescription.
Adjuvant and metastatic schedules differ, and the oncology specialist will write the precise dose in mg/m² or total mg per dose.
Always follow the oncology prescription precisely and carry a written dosing calendar.
Adjustments For Comorbidities
When are dose changes needed?
Renal impairment often requires dose adjustment based on creatinine clearance thresholds; moderate to severe impairment may need dose reduction or avoidance.
Elderly patients may require closer monitoring and possible reductions due to renal decline and frailty.
Toxicities graded ≥3 (severe) usually prompt treatment interruption and restart at a reduced dose per oncology guidance.
Common triggers to withhold or interrupt a dose include temperature ≥38°C, severe diarrhoea, severe hand–foot syndrome, significant bleeding or severe mucositis.
| Regimen Example | Typical Schedule | Renal Adjustment / Notes |
|---|---|---|
| Adjuvant Colon (example pattern) | Twice daily for 14 days then 7 days off. | 150 mg and 500 mg tablets allow dose calculation; assess creatinine clearance before each cycle. |
| Metastatic Breast / CRC (example) | Continuous cycles of 14 days on / 7 days off or alternative schedules as prescribed. | Reduce dose for CrCl 30–50 mL/min; avoid if CrCl <30 mL/min unless specialist advice. |
- When To Withhold Doses: Fever ≥38°C.
- When To Withhold Doses: Severe diarrhoea (persistent despite anti‑diarrhoeal measures).
- When To Withhold Doses: Grade 3–4 hand–foot syndrome or severe mucositis.
Q&A — “What If I Miss A Dose?”
Q: What if I miss a dose of Xeloda?
A: If the missed dose is remembered the same day, take it as soon as possible and continue the normal schedule.
A: Do not double up doses to make up for a missed dose.
A: If it is close to the time for your next dose, skip the missed dose and resume the usual timing.
A: For oncology‑specific questions about missed doses within a cycle, contact the treating nurse, oncologist or local pharmacist right away.
A: Keep the dosing calendar with cycle dates and bring it to all clinic visits so adherence can be reviewed.
Interaction Chart
Food And Drinks
How should Xeloda be taken with food and alcohol?
Capecitabine tablets are usually taken within 30 minutes after a meal to reduce gastrointestinal upset.
Avoid taking doses on an empty stomach unless specifically instructed by the oncology team.
Avoid excessive alcohol while on treatment as it may worsen diarrhoea, mucositis and hepatic stress.
Caffeine has no major direct interaction with capecitabine but monitor for increased gut upset or sleep disturbance while unwell.
Common Drug Conflicts
Which medicines interact with capecitabine?
Concomitant warfarin use has been associated with increased INR and bleeding risk and requires close INR monitoring.
Enzyme‑inducing anticonvulsants and some antivirals or antifungals may alter metabolism and require specialist review.
Concomitant use with sorivudine or chemically related compounds is contraindicated due to severe interaction risk.
Live vaccines are generally avoided in immunosuppressed patients receiving cytotoxic chemotherapy.
| Drug/Class | Interaction Effect | Suggested Management |
|---|---|---|
| Warfarin | Increased INR and bleeding risk. | Increase INR monitoring frequency; consider alternative anticoagulation after specialist advice. |
| Sorivudine / Analogs | Severe, potentially fatal interaction. | Contraindicated; do not co‑administer. |
| Enzyme‑inducing Anticonvulsants | May reduce exposure or alter effect of chemotherapy. | Review with treating specialist; adjust therapy as needed. |
| Live Vaccines | Increased risk of infection in immunosuppressed patients. | Avoid unless advised by treating team; use inactivated vaccines where appropriate. |
Always give a complete medicines list, including OTC and complementary medicines, to the treating team and community pharmacist.
User Reports & Trends
What are patients in Australia commonly reporting?
Common patient‑reported themes include hand–foot syndrome, diarrhoea, fatigue, nausea and the need for dose modifications.
Many people appreciate oral therapy convenience compared with intravenous infusions but stress the importance of adherence and monitoring for side effects.
Rural patients often value telehealth and home delivery from large pharmacy chains but report occasional delays in dispensing and access to oncology nursing support.
Patients routinely report the need for clear written dosing instructions and easy access to specialist nursing advice.
- Most Common Symptoms Reported: Hand–foot syndrome, diarrhoea, fatigue, nausea.
- Typical Onset Timeline: Symptoms often appear within the first 1–6 weeks of treatment depending on the individual and regimen.
- Self‑Management Strategies: Use moisturisers for hand–foot syndrome and cool packs; carry anti‑diarrhoeal medication only as instructed by a clinician.
Patients are encouraged to report severe or unexpected symptoms promptly to the oncology clinic or GP and to report adverse events to the TGA.
Access & Purchase Options
National Chains
Where can Xeloda be dispensed in Australia?
Capecitabine is a prescription medicine and community pharmacy dispensing follows PBS and hospital rules when applicable.
Major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart routinely dispense oncology medicines under appropriate scripts and criteria when supply permits.
Some community pharmacies offer home delivery and dose‑packing services to help patients manage complex tablet schedules.
In our online pharmacy, xeloda is available without a prescription, with discreet delivery to Australia in 9-21 days.
Online Pharmacies And Telehealth E-Prescriptions
Many clinics accept e‑prescriptions after telehealth consultations for chronic medicines, and some oncology shared‑care models enable GP‑led prescribing for community supply.
Online pharmacies can facilitate repeat dispensing but oncology medicines often require hospital supply or authorised community dispensing with appropriate documentation.
| Pharmacy Source | Typical Lead Time | PBS Subsidy Requirements | Prescription Type Accepted |
|---|---|---|---|
| Hospital Pharmacy | Same day to 3 days | Usually supplied as part of hospital care; PBS criteria may differ. | Hospital oncology script |
| Community Pharmacy Chain | 1–3 days | Dispense under PBS if criteria met and authority granted. | Oncologist or authorised GP script |
| Online Pharmacy | 2–7 days depending on verification and supply | Subsidy applies when PBS criteria and authority scripts are provided. | E‑prescription or scanned hospital script |
Verify supply before travel and coordinate with the hospital pharmacy for rural or remote access arrangements.
Mechanism & Pharmacology
Simplified Explanation
How does capecitabine work against cancer?
Capecitabine is a prodrug that is metabolised in the body to 5‑fluorouracil (5‑FU), which disrupts DNA synthesis in rapidly dividing cancer cells.
The ATC code L01BC06 classifies capecitabine as a pyrimidine analogue antimetabolite.
Clinical Terms
Key pharmacology points are that capecitabine is orally absorbed, converted through hepatic metabolism to intermediate metabolites and selectively activated within tumours.
Renal clearance and hepatic metabolism are relevant to dosing and safety, hence baseline and ongoing monitoring is required.
- Prodrug: A medication given in an inactive or less active form that is converted to the active drug in the body.
- Antimetabolite: A drug that interferes with DNA and RNA synthesis in rapidly dividing cells.
- 5‑FU: The active cytotoxic metabolite generated from capecitabine.
A simple suggested diagram: Oral tablet → Liver metabolism → Tumour activation to 5‑FU.
Understanding the mechanism helps explain mucosal, gastrointestinal and haematological toxicities and the rationale for treatment breaks.
Indications & Off‑Label Uses
Approved Indications By TGA
What is capecitabine officially used for?
International product information describes core uses including adjuvant colon cancer, metastatic colorectal cancer, metastatic breast cancer, and gastric cancer in approved markets.
Confirm the exact TGA approvals and PBS listings for current Australian indications and subsidy criteria on the respective government registers.
Off‑Label Uses In Australian Clinical Practice
Specialist clinicians sometimes use capecitabine off‑label as part of combination regimens or for rare tumours, with documented rationale and informed consent.
Off‑label use should be supported by multidisciplinary team discussion and reference to current evidence and guidelines such as eviQ Cancer Treatments Online.
- Approved Uses (General): Adjuvant colon cancer, metastatic colorectal cancer, metastatic breast cancer, gastric cancer in some markets.
- Common Off‑Label Uses: Specialist combinations or tumour types under clinical judgement and documented consent.
- Checklist For Off‑Label Use: Obtain informed consent, document clinical rationale, consult multidisciplinary team and reference guidelines.
Key Clinical Findings
What recent evidence matters between 2022 and 2026?
Capecitabine continues to be used as an oral alternative to intravenous 5‑FU in many settings with comparable efficacy in numerous regimens.
Recent research has focused on oral‑only combinations, dose optimisation strategies and monitoring for cardiotoxicity signals.
Real‑world Australian analyses emphasise toxicity management, adherence and the impact of rural access on outcomes.
| Study / Source | Population | Outcome | Implication For Practice |
|---|---|---|---|
| Randomised Trials (Recent) | Adjuvant and Metastatic Patients | Comparable efficacy to 5‑FU regimens in many settings. | Supports oral capecitabine as an option where appropriate and monitored. |
| Registry / Real‑World Analyses | Australian Cohorts | Highlights toxicity management and adherence challenges. | Emphasises need for close follow up, especially in rural populations. |
| Safety Signals Reviews | Patients With Cardiac History | Reports of cardiotoxicity require vigilance. | Cardiology review recommended when indicated. |
Clinicians should review full trial reports and guideline updates such as eviQ before altering local practice.
Alternatives Matrix
PBS‑Listed Alternatives Comparison
| Alternative | Route | PBS Status | Pros | Cons |
|---|---|---|---|---|
| 5‑Fluorouracil (5‑FU) + Leucovorin | Intravenous | Some regimens PBS‑listed depending on indication | Established efficacy; no oral adherence issues. | Requires infusion access, clinic visits and IV lines. |
| S‑1 (where available) | Oral | Variable by country; check local availability | Oral option with different toxicity profile. | Availability and subsidy vary; not identical efficacy profile. |
Pros And Cons Checklist
- Pros: Oral convenience; outpatient administration; avoids infusion lines and associated complications.
- Cons: Patient adherence responsibility; specific oral toxicities; interactions and renal dosing requirements.
- Patient Suitability Considerations: Tumour type, performance status, comorbidities, ability to adhere, and PBS funding.
Common Questions
Which practical questions do patients ask most often?
- How To Take Xeloda: Usually within 30 minutes after a meal as prescribed by the oncology team.
- Managing Nausea: Use antiemetics prescribed by the clinician and take small frequent meals.
- When To Contact Clinic: Fever, persistent or severe diarrhoea, severe mucositis, bleeding or signs of infection.
- Contraception Requirements: Pregnancy testing and effective contraception are required for people of childbearing potential.
- Storage Of Tablets: Keep in original pack, in a cool dry place away from children.
Pharmacy Counselling Prompts: Confirm home support, review all medicines including OTCs and supplements, advise on side‑effect mitigation and provide a written dosing calendar.
Provide a patient wallet card with drug name, dose, cycle dates and emergency contact numbers.
Price & Access Comparison
Comparison Table — Pharmacy / Source, Typical Price Range, PBS Subsidy, Prescription Required
| Source | Typical Out‑Of‑Pocket | PBS Subsidy | Prescription Required |
|---|---|---|---|
| Hospital Pharmacy | Varies | Provided in hospital settings as per public policy | Hospital oncology script |
| Community Pharmacy | Varies by pharmacy and concession status | Yes when PBS criteria and authority are met | Oncologist or authorised GP script |
| Online Pharmacy | Varies; delivery fees may apply | Yes when PBS criteria met and documentation provided | E‑prescription or scanned script |
Access Checklist
- Confirm PBS criteria and authority requirements before ordering.
- Allow 48–72 hours for supply if special authorisation or hospital coordination is required.
- Ask about pack sizes (150 mg and 500 mg) and dose‑packing services.
- Consider home delivery options if mobility or distance is an issue.
Exact prices and PBS copayments change regularly and should be checked with the pharmacy or PBS website at the point of care.
Registration & Regulation
TGA Approval
Is Xeloda registered in Australia?
Xeloda (capecitabine) is an antineoplastic prescription product in international records and should be checked on the Australian Register of Therapeutic Goods (ARTG) for the current entry and sponsor details.
PBS Subsidy Details
PBS listings are indication‑ and criteria‑specific and require authority scripts when subsidy rules apply.
Patients should check the PBS schedule for the latest item numbers and patient co‑payment amounts relevant to their treatment.
- ARTG vs PBS: ARTG registers the product; PBS determines subsidy and authority requirements.
- What To Bring To Pharmacy: Original script, concession card if applicable, and any hospital paperwork authorising community supply.
Report suspected adverse events to the TGA and enquire with hospitals about clinical trials or expanded access programmes where appropriate.
Storage & Handling
Household Storage In Australian Climate
How should Xeloda be stored at home in Australia?
Store capecitabine in the original packaging and protect from moisture, heat and direct sunlight.
Aim to keep tablets below 25°C where possible, and avoid storing them in bathrooms or above kitchen benches where humidity and heat fluctuate.
Australian summers can exceed recommended storage temperatures so choose a cool, dry, shaded spot inside the home.
Cold‑Chain Handling For Pharmacies
Xeloda is not a cold‑chain product and ambient handling according to the manufacturer’s storage instructions is acceptable.
Pharmacies should follow standard manufacturer guidance, expiry handling and ensure secure storage away from unauthorised access.
| Setting | Storage Advice |
|---|---|
| Home | Original pack, cool dry place, out of reach of children. |
| Pharmacy | Ambient storage per manufacturer; secure and labelled. |
Disposal: Return unused tablets to a pharmacy for safe disposal; do not flush or discard in household rubbish.
Guidelines For Proper Use
Australian Pharmacist Counselling Style
What should a pharmacist cover in a counselling session?
Confirm the indication and exact cycle dates with the patient and treating team.
Explain the dosing schedule clearly and provide a written dosing calendar with times and cycle start/end dates.
Emphasise adherence and review side‑effect red flags including fever, severe diarrhoea, bleeding and chest pain.
Discuss contraception requirements and ensure pregnancy testing is completed where applicable.
Provide contact details for the oncology nurse and local pharmacist for urgent queries.
Patient Advice From PBS And National Health Authorities
Reinforce adherence to guidance from eviQ, the TGA and PBS where applicable.
Encourage use of support services such as Cancer Council and local health district resources for counselling and financial assistance.
- Discharge Counselling Checklist: Dose times, warning signs, emergency contacts, and written dosing calendar.
- Patient Handout Template Suggestion: Drug name, dose, cycle dates, side‑effect checklist, and oncology contact numbers.
Final Practical Tips: Keep a symptom diary, bring all medicines to clinic visits and request pharmacist review of concomitant medicines for interactions.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 14–21 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 9–14 days |
| Geelong | Victoria | 9–14 days |
| Cairns | Queensland | 14–21 days |
| Townsville | Queensland | 14–21 days |
| Alice Springs | Northern Territory | 14–21 days |